ArticleEpigenetics & chromatin2026
CancerSubtyper: a deep learning framework for cancer subtyping through DNA methylation data.
Article in Epigenetics & chromatin, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
backgroundMolecular subtyping is essential for precision oncology, enabling the classification of tumors into biologically and clinically relevant categories. DNA methylation has emerged as a promising biomarker for cancer subtyping, yet its application remains limited by high dimensionality, batch effects, and the lack of automated, user-friendly analytical tools.
resultsHere, we present CancerSubtyper, an end-to-end computational framework for deep learning-based cancer subtyping using DNA methylation data, which is accessible through an intuitive web interface designed to support interactive exploration and downstream analysis. CancerSubtyper integrates two complementary models: a semi-supervised classifier for cancers with well-established subtypes, and a hybrid framework that integrates supervised and unsupervised learning to identify novel subtypes. The framework automatically performs preprocessing, feature selection, batch correction, and cancer subtyping while offering interactive visualization for subtype exploration and validation.
conclusionBy providing an automated, end-to-end workflow accessible through a user-friendly web interface, CancerSubtyper lowers the barrier to large-scale methylation analysis and provides a powerful tool for molecular subtyping and precision oncology research. The framework is freely accessible at https://github.com/ycheung5/cancersubtyper/ .
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.